Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.OtgQHJex.js ...

In a recent study, majority non-White communities had at least 40 percent lower mean adjusted per-capita distribution than majority White communities.

More New Yorkers received scripts for buprenorphine, a med used to treat opioid addiction, amid fight against record-high ...

Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose ...

Other parts of China's plan will include a pledge to not devalue the yuan, an offer to make more investments in the U.S and a ...

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

[16] This is believed to be a class effect and other opioids could be substituted. In the older adult a low dose (as low as 100 mg twice a day) should be started, and the drug should be titrated ...

Business Secretary Jonathan Reynolds says there is no need for tariffs because the US has no goods trade deficit with the UK.

British Columbia's attorney general says the B.C. Supreme Court has certified the province's class-action lawsuit against opioid manufacturers and distributors. Niki Sharma says B.C. can now ...

Tris Pharma has pointed to a phase 3 win for its pain relief drug as demonstrating the candidate’s potential to help resolve the opioid crisis. The company tested cebranopadol, a dual nociceptin ...